ArticleOpen veterinary journal2025
Role of
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Brassica is one of the herbs with potential in the field of medicine, containing active compounds such as glucosinolates. These compounds can be hydrolyzed into indole-3-carbinol (I3C) and 3,3'-diindolylmethane, which have been shown to have a positive impact on health. The stem part of cauliflower is often not utilized; therefore, it was used in this study. Aim: This study aimed to detect the presence of I3C in cauliflower stem powder (BOVB) and evaluate its potential as an aromatase inhibitor Methods: This study used cauliflower stems that were freeze-dried and milled into powder. The experimental animals used were Sprague-Dawley rats with five treatments: P1 = distilled water (negative control); P2 = pure I3C 10.34 mg/day (positive control); P3 = 171.5 g/day; P4 = 343 g/day; and P5 = 686 g/day. Treatment was conducted for 56 days with blood serum collection on day 7 (week 1), day 28 (week 4), day 42 (week 6), and day 56 (week 8). Blood serum was tested using an enzyme-linked immunosorbent assay to measure serum testosterone and aromatase levels. Data were statistically analyzed using two-way analysis of variance and the Duncan test. Results: Rats administered BOVB suspension after 56 days showed a significant decrease in aromatase levels in the blood serum (P4 and P5) compared with those not administered (P1) in the eighth week. In contrast, serum testosterone levels tended to increase but showed no significant change in all groups and all weeks. In the eighth week, rats also showed a significant increase in body weight in the groups given BOVB suspension (P3, P4, and P5) compared to those not given the BOVB suspension (P1). Conclusion: BOVB supplementation significantly decreased serum aromatase levels, increased body weight, and showed a non-significant upward trend in testosterone levels. Further research is needed to elucidate the metabolic pathways, determine optimal safe dosages, and evaluate long-term clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.